Rituximab may affect T lymphocyte subsets balance in primary membranous nephropathy

被引:1
|
作者
Zhang, Yuanyuan [1 ,2 ]
Yang, Jingjing [3 ]
Li, Jianzhong [1 ]
Sun, Jiani [1 ]
Zhou, Ling [1 ]
Xu, Deyu [1 ]
Sha, Wengang [1 ]
Dai, Lan [4 ]
Shen, Lei [1 ]
机构
[1] Soochow Univ, Dept Nephrol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Nanjing Univ, Suzhou Hosp, Affiliated Hosp, Dept Nephrol,Med Sch, Suzhou, Peoples R China
[3] BenQ Med Ctr, Dept Nephrol, Suzhou, Peoples R China
[4] Soochow Univ, Jiangsu Inst Hematol, Minist Hlth, Key Lab Thrombosis & Hemostasis,Affiliated Hosp 1, Suzhou, Peoples R China
关键词
Rituximab; Primary membranous nephropathy; T lymphocyte subsets; B lymphocyte cells; Anti-PLA2R antibody; RECEPTOR; CHILDREN; CELLS;
D O I
10.1186/s12882-024-03521-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe aim of this study was to investigate the effects and significance of rituximab (RTX) on the levels of T lymphocyte subsets in patients diagnosed with primary membranous nephropathy (PMN).MethodsA total of 58 PMN patients and 25 healthy donors were chosen as the subjects. Among the PMN patients, 40 individuals received RTX treatment and completed at least 6 months of follow-up. All subjects underwent flow cytometry analysis to determine the peripheral blood lymphocyte subsets. The changes in anti-PLA2R antibody titers and 24-hour urinary protein levels were evaluated by ELISA and Biuret method before and after treatment.Results(1) The PMN group exhibited a significantly greater percentage of peripheral blood CD3-CD19+ B cells than the healthy group, which is consistent with the findings of previous reports. Additionally, compared with those in the peripheral blood of healthy individuals, the numbers of CD4+ central memory T cells, CD4+ effector memory T cells, CD4+/CD8+, and CD4+CD25+ T cells in the PMN peripheral blood were markedly greater. However, the number of peripheral blood Treg cells was reduced in the PMN group. (2) After 6 months of RTX treatment, PMN patients exhibited significant decreases in anti-PLA2R antibody titers, 24-hour urinary protein levels, and peripheral blood CD3-CD19+ B cells. Importantly, RTX administration decreased CD4+CD25+ T cells and CD4+/CD8+ in the peripheral blood of PMN patients and improved Treg cell levels. (3) RTX treatment induced alterations in the CD4+ T lymphocyte subsets in PMN patients, which did not correlate with B lymphocyte counts or anti-PLA2R antibody titers.ConclusionsRTX treatment might have a beneficial impact on cellular immunity by effectively restoring the balance of CD4+ T lymphocyte subsets in PMN patients, which is beyond its effects on B cells and antibody production.Trial registrationThe research was registered at the First Affiliated Hospital of Soochow University. Registration Number: MR-32-23-016211. Registration Date: May 31, 2023.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?
    Pasquale Esposito
    Fabrizio Grosjean
    Filippo Mangione
    Maria Valentina Domenech
    Teresa Rampino
    Clinical and Experimental Nephrology, 2018, 22 : 208 - 209
  • [22] Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?
    Esposito, Pasquale
    Grosjean, Fabrizio
    Mangione, Filippo
    Domenech, Maria Valentina
    Rampino, Teresa
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (01) : 208 - 209
  • [23] Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
    Lin, Jamie S.
    Wang, Daniel Y.
    Mamlouk, Omar
    Glass, William F.
    Abdelrahim, Maen
    Yee, Cassian
    Abudayyeh, Ala
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [24] Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study
    Liang, Hao
    Deng, Zhenling
    Niu, Shu
    Kong, Weijie
    Liu, Yang
    Wang, Song
    Li, Haiyan
    Wang, Yue
    Zheng, Danxia
    Liu, Dongyang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] Low-dose rituximab is poorly effective in patients with primary membranous nephropathy
    Moroni, Gabriella
    Depetri, Federica
    Del Vecchio, Lucia
    Gallelli, Beniamina
    Raffiotta, Francesca
    Giglio, Elisa
    Brunini, Francesca
    D'Amico, Marco
    Longhi, Selena
    Radice, Antonella
    Messa, Piergiorgio
    Sinico, Renato Alberto
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (10) : 1691 - 1696
  • [26] B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab
    Rosenzwajg, Michelle
    Languille, Eva
    Debiec, Hanna
    Hygino, Joana
    Dahan, Karine
    Simon, Tabassome
    Klatzmann, David
    Ronco, Pierre
    KIDNEY INTERNATIONAL, 2017, 92 (01) : 227 - 237
  • [27] Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study
    Zhang, Shasha
    Huang, Jing
    Dong, Jianwei
    Li, Zhuo
    Sun, Mengyao
    Sun, Yujiao
    Chen, Bing
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [28] Evaluating the Efficacy of Rituximab in Primary Membranous Nephropathy: An Observational Study from Southern India
    Saigal, Megha
    Guditi, Swarnalatha
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 514 - 514
  • [29] Comparison of Outcomes Between Rituximab and Cyclophosphamide for Primary Membranous Nephropathy: A Single Center Experience
    Hussain, Azm U.
    Sarween, Nadia
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 502 - 502
  • [30] Ofatumumab in Rituximab-Resistant and RituximabIntolerant Patients With Primary Membranous Nephropathy: A Case Series
    Podesta, Manuel Alfredo
    Trillini, Matias
    Portalupi, Valentina
    Gennarini, Alessia
    Tomatis, Federica
    Villa, Alessandro
    Perna, Annalisa
    Rubis, Nadia
    Remuzzi, Giuseppe
    Ruggenenti, Piero
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (03) : 340 - 349.e1